

Cover Story
Clinical
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.
Health Equity
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for November 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - NCI summarizes changes to the CCSG NOFO
- City of Hope’s BMT program performs 20,000th transplant
49-year history creates 20,000 tomorrows